Table 4.
Summary of vaccine efficacy with MCT® and Alum –depot adjuvants. The respective studies conjugated CuMVTT with TRAP or a CSP antigen from P. vivax (independent of CuMVTT). Formulations were compared against vaccines formulated with Alum.
| Protection against Plasmodium berghei/vivax | |||||
|---|---|---|---|---|---|
| Formulations screened | Humoral response | Cellular response (CD8+ T cells) | Vaccine efficacy in survival challenge | Reference | |
|
CMVtt-PvTRAP + MCT®
|
** (PvTRAP + MCT®) IgG2b > IgG2a > IgG1 |
** (PvTRAP + MCT®) | *** (PvTRAP + MCT®) | (52) | |
|
CSP + MCT®
|
** (CSP + MCT®) IgG2a > IgG2b > IgG1 |
N.D |
* (CSP + MCT®) |
(53) | |
***p = 0.0001 **p = 0.001; *p = 0.01 (one week after second boost); N.D; not determined.